ClinicalTrials.gg
CompletedNCT01479621Updated Jun 5, 2017Results posted

A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler in Adolescents and Adults Who Have Asthma That is Not Controlled by Asthma Medications Not Containing Steroids

A Phase 2 interventional study of Fp MDPI and Flovent Diskus in Asthma, sponsored by Teva Branded Pharmaceutical Products R&D, Inc.. Completed at 189 sites in 9 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2017-06-05.

Sponsored by Teva Branded Pharmaceutical Products R&D, Inc. (part of Teva Pharmaceutical Industries, Ltd.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
909
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 147 studies testing fluticasone in Asthma — 1 open to participants now, 4 under way, 2 of them phase 3. Fluticasone · Asthma.

Enrollment
9th of 146
909 · median 100
Started
2012
with 12 others
Phase 2
25 of 147
none open now
Registered
83rd of 147
by date
Lead sponsor
10 of 147
Teva Branded Pharmaceutical Products R&D, Inc.

Among the 147 studies testing fluticasone in Asthma, this one is the 9th largest by enrollment of the 146 interventional ones that give a count, is one of 13 that started in 2012, is one of 25 in phase 2, and was the 83rd registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

1 of the 147 studies testing fluticasone in Asthma is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About fluticasone

Fluticasone: first FDA approval 1990 (CUTIVATE), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 147 studies testing fluticasone in Asthma, or all of them as a file.
02

Study summary

This is a randomized, double-blind, placebo- and open-label active controlled, parallel-group, multicenter, dose ranging study in male or female subjects ages 12 years and older with persistent asthma who are uncontrolled on non-steroidal therapy. The primary objective of this study is to evaluate the dose response, efficacy and safety of 4 different doses of fluticasone propionate delivered as Fluticasone Propionate DPI (Dry Powder Inhaler) when administered twice daily.

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • Dose Ranging
  • Fluticasone Propionate
  • Dry Powder Inhaler (DPI)
  • Non-steroidal
  • Asthma
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written /assent signed and dated by the subject and/or parent /legal guardian before conducting any study related procedure.
  2. Male or female 12 years and older, as of the Screening Visit. Male or female 18 years and older, as of the Screening Visit, in countries where local regulations or the regulatory status of study medication permit enrollment of adults only.
  3. General good health, and free of any concomitant conditions or treatment that could interfere with study conduct, influence the interpretation of study observations/results, or put the subject at increased risk during the study.
  4. Asthma Diagnosis: Asthma as defined by the National Institutes of Health (NIH).
  5. Severity of Disease: A best (FEV1) of 40%-85% of the predicted normal value during the Screening Visit. NHANES III predicted values will be used for subjects aged ≥12 years and adjustments to predicted values will be made for African American subjects.
  6. Reversibility of Disease: Demonstrated a ≥15% reversibility of FEV1 within 30 minutes following 2 inhalations of albuterol/salbutamol inhalation aerosol (if required, spacers are permitted for reversibility testing only) at the Screening Visit. If a subject fails to demonstrate an increase in FEV1 ≥15%, then the subject is not eligible for the study and will not be allowed to re-screen.
  7. Current Asthma Therapy: Subjects must be on a short-acting β2-agonist alone or a non- maintenance medication (with or without a short-acting β2-agonist) for ≥ 3 months preceding the Screening Visit. Subjects must not have used an inhaled corticosteroid for at least 6 weeks preceding the Screening Visit.

    Exception: Based upon the investigator's judgment that there is no inherent harm in changing the subject's current ICS therapy and the subject provides consent, subjects on low dose ICS (100mcg Fp BID or equivalent) may be switched to a short-acting β2 agonist alone at a Pre-screening Visit. The subject will be required to return to the clinic to complete the Screening Visit once the 2-week has been completed.

  8. Short-Acting β2-Agonists: All subjects must be able to replace their current short-acting β2-agonists with albuterol/salbutamol inhalation aerosol at the Screening Visit for use as needed for the duration of the study. The use of spacer devices with the metered dose inhaler (MDI) will not be allowed during the study with exception of its use during reversibility testing at the Screening Visit. Nebulized albuterol/salbutamol will not be allowed at any time during the study. Subjects must be able to withhold all inhaled short-acting beta sympathomimetic bronchodilators for at least 6 hours prior to all study visits.
  9. If female, is currently not pregnant, breast feeding, or attempting to become pregnant, has a negative serum pregnancy test, and is of

    1. Non-, defined as:

      • Before menarche or > or =1 year or
      • Surgically sterile (tubal ligation, bilateral oophorectomy, or hysterectomy) or
      • Congenital sterility or
      • Diagnosed as infertile and not undergoing treatment to reverse infertility or is of
    2. Child-bearing potential, willing to commit to using a consistent and acceptable method of as defined below for the duration of the study:

      • Systemic contraception used for > or = 1 month prior to screening, including birth control pills, transdermal patch (Ortho Evra®), vaginal ring (NuvaRing®), levonorgesterel (Norplant®), or injectable progesterone (Depo-Provera®) or
      • Double barrier methods (condoms, cervical cap, diaphragm, and vaginal contraceptive film with spermicide) or
      • Intrauterine device (IUD) or is of
    3. Child-bearing potential and not sexually active, willing to commit to using a consistent and acceptable method of birth control as defined above for the duration of the study, in the event the subject becomes sexually active.
  10. Capable of understanding the requirements, risks, and benefits of study participation, and, as judged by the investigator, capable of giving informed consent/assent and being compliant with all study requirements (visits, record-keeping, etc).

Exclusion criteria

Exclusion Criteria:

  1. History of life-threatening asthma that is defined for this protocol as an asthma episode that required intubation and/or was associated with hypercapnea, respiratory arrest or hypoxic seizures.
  2. Culture-documented or suspected bacterial or viral infection of the upper or lower respiratory tract, sinus, or middle ear that is not resolved within 2 weeks prior to the Screening Visit. In addition, the subject must be excluded if such infection occurs between the Screening Visit and the Randomization Visit.
  3. Any asthma exacerbation requiring oral within 3 months of the Screening Visit. A subject must not have had any hospitalization for asthma within 6 months prior to the Screening Visit.

    Note: An exacerbation of asthma is defined as any worsening of asthma requiring any treatment other than rescue albuterol/salbutamol HFA MDI and/or the subject's regular non-corticosteroid maintenance treatment. This includes requiring the use of systemic corticosteroids and/or emergency room visit or hospitalization, a change in the subject's regular non-corticosteroid maintenance treatment, or the addition of other asthma medications.

  4. Presence of glaucoma, cataracts, ocular herpes simplex, or other than basal cell carcinoma.
  5. Historical or current evidence of a disease including, but not limited to: cardiovascular (e.g., congestive heart failure, known aortic aneurysm, clinically significant cardiac arrhythmia or coronary heart disease), hepatic, renal, hematological, neuropsychological, endocrine (e.g., uncontrolled diabetes mellitus, uncontrolled thyroid disorder, Addison's disease, Cushing's syndrome), gastrointestinal (e.g., poorly-controlled peptic ulcer, GERD), or pulmonary (e.g., chronic bronchitis, emphysema, bronchiectasis with the need for treatment, cystic fibrosis, bronchopulmonary dysplasia, ). Significant is defined as any disease that, in the opinion of the investigator, would put the safety of the subject at risk through participation, or which could affect the efficacy or safety analysis if the disease/condition exacerbated during the study.
  6. Have any of the following conditions that, in the judgment of the investigator, might cause participation in this study to be detrimental to the subject, including, but not limited to:

    • Current malignancy excluding basal cell carcinoma; History of malignancy is acceptable only if the subject has been in remission for one year prior to the Screening Visit. (Remission is defined as no current evidence of malignancy and no treatment for the malignancy in the 12 months prior to the Screening Visit)
    • Current or untreated tuberculosis; History of tuberculosis is acceptable only if a subject has received an approved prophylactic treatment regimen or an approved active treatment regimen and has had no evidence of active disease for a minimum of 2 years • Uncontrolled hypertension (systolic BP ≥160 or diastolic BP >100)
    • Stroke within 3 months prior to the Screening Visit
    • Immunologic compromise
  7. History of a positive test for , or infection.
  8. Clinical visual evidence of oral candidiasis at the Screening Visit.
  9. History of any adverse reaction, including immediate or delayed to any β2-agonist, sympathomimetic drug, or any intranasal, inhaled, or systemic corticosteroid therapy. Known or suspected sensitivity to the constituents of the dry powder inhalers (Spiromax or Diskus) used in the study (i.e., lactose).
  10. History of severe allergy to milk protein.
  11. Use of systemic, oral or depot corticosteroids within 12 weeks prior to the Screening Visit

    • Use of topical corticosteroids (≤1% hydrocortisone cream) for dermatological disease is permitted
    • Use of intranasal corticosteroids at a stable dose for at least 4 weeks prior to the Screening Visit and throughout the study is permitted
  12. Use of medications within 4 weeks prior to the Screening Visit and during the study.
  13. Immunotherapy at a stable dose for at least 90 days prior to the Screening Visit and throughout the study for the treatment of allergies is permitted.
  14. Use of potent Cytochrome P450 3A4 () inhibitors (e.g., ritonavir, ketoconazole, itraconazole) within 4 weeks prior to the Screening Visit.
  15. History of alcohol or drug abuse within two years preceding the Screening Visit.
  16. Current smoker or a smoking history of 10 pack years or more (a pack year is defined as smoking 1 pack of cigarettes/day for 1 year). A subject may not have used tobacco products within the past one year (e.g., cigarettes, cigars, chewing tobacco, or pipe tobacco).
  17. Study participation by clinical investigator site employees and/or their immediate relatives.
  18. Study participation by more than one subject from the same household at the same time. However, after the study completion or discontinuation by one subject another subject from the same household may be screened.
  19. Participation in any drug study within the 30 days (starting at the final follow-up visit) preceding the Screening Visit or planned participation in another investigational drug study at any time during this study.
  20. Pregnancy, nursing, or plans to become pregnant or donate gametes (ova or sperm) for in vitro fertilization during the study period or for 30 days following the subject's last study related visit (for eligible subjects only - if applicable). Eligible female subjects unwilling to employ appropriate measures to ensure that pregnancy will not occur during the study will be excluded.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
909 participants (actual)

Study arms

  • Experimental
    Fp MDPI 12.5 mcg

    Fluticasone propionate (Fp) 12.5 mcg per dose twice a day (for a total daily dose of 25 mcg) using a multidose dry powder inhaler (MDPI) for 12 weeks in a double-blind manner. During the run-in and the treatment periods, all subjects replaced their current rescue medication with albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) (90 mcg/actuation) for use on an as needed basis for the relief of asthma symptoms.

    Drug: Fp MDPI · Drug: albuterol/salbutamol

  • Experimental
    Fp MDPI 25 mcg

    Fluticasone propionate (Fp) 25 mcg per dose twice a day (for a total daily dose of 50 mcg) using a multidose dry powder inhaler (MDPI) for 12 weeks in a double-blind manner. During the run-in and the treatment periods, all subjects replaced their current rescue medication with albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) (90 mcg/actuation) for use on an as needed basis for the relief of asthma symptoms.

    Drug: Fp MDPI · Drug: albuterol/salbutamol

  • Experimental
    Fp MDPI 50 mcg

    Fluticasone propionate (Fp) 50 mcg per dose twice a day (for a total daily dose of 100 mcg) using a multidose dry powder inhaler (MDPI) for 12 weeks in a double-blind manner. During the run-in and the treatment periods, all subjects replaced their current rescue medication with albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) (90 mcg/actuation) for use on an as needed basis for the relief of asthma symptoms.

    Drug: Fp MDPI · Drug: albuterol/salbutamol

  • Experimental
    Fp MDPI 100 mcg

    Fluticasone propionate (Fp) 100 mcg per dose twice a day (for a total daily dose of 200 mcg) using a multidose dry powder inhaler (MDPI) for 12 weeks in a double-blind manner. During the run-in and the treatment periods, all subjects replaced their current rescue medication with albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) (90 mcg/actuation) for use on an as needed basis for the relief of asthma symptoms.

    Drug: Fp MDPI · Drug: albuterol/salbutamol

  • Experimental
    Placebo MDPI

    Placebo twice a day using a multidose dry powder inhaler (MDPI) for 12 weeks in a double-blind manner. During the run-in and the treatment periods, all subjects replaced their current rescue medication with albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) (90 mcg/actuation) for use on an as needed basis for the relief of asthma symptoms.

    Drug: albuterol/salbutamol · Drug: Placebo MDPI

  • Experimental
    Flovent Diskus 100mcg

    Fluticasone propionate (Fp) 100 mcg per dose twice a day (for a total daily dose of 200 mcg) using a multidose dry powder inhaler (MDPI) for 12 weeks in an open-label manner. During the run-in and the treatment periods, all subjects replaced their current rescue medication with albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) (90 mcg/actuation) for use on an as needed basis for the relief of asthma symptoms.

    Drug: Flovent Diskus · Drug: albuterol/salbutamol

Interventions

  • Fp MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate (Fp) dispersed in a lactose monohydrate excipient and contained within a reservoir. A metered dose of drug is delivered to a dose cup via an air pulse activated when the cap is opened. During the treatment period, participants were randomized to 12.5, 25, 50 or 100 mcg of Fp one inhalation twice a day for a total daily dose of 25, 50, 100 or 200 mcg. Study drug was administered in the morning and in the evening

    Also known as: Fluticasone propionate, Fp SPIROMAX® Inhalation Powder

  • Flovent Diskus contains the active ingredient fluticasone propionate (Fp). Flovent Diskus 100 mcg was used twice a day, once in the morning and evening, for a total daily dose of 200 mcg of Fp. This therapy was not blinded as the inhaler device was different than the MDPI used in the other treatment arms.

    Also known as: Fluticasone propionate

  • Drugalbuterol/salbutamol

    Drug page: Albuterol

    A short-acting β2-adrenergic agonists (SABA), albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI), was provided to be used as needed for the relief of asthma symptoms during both the run-in and treatment periods (to replace the subject's current rescue medication).

    Also known as: short-acting β2-adrenergic agonists

  • DrugPlacebo MDPI

    Placebo multidose dry powder inhaler in the morning and evening. Placebo MDPI was provided in devices identical in appearance to Fp MDPI.

06

What researchers measure

Primary outcomes

  1. Change From Baseline In Trough (Morning Predose And Pre-Rescue Bronchodilator) Forced Expiratory Volume In 1 Second (FEV1) Over The 12-Week Treatment Period

    Trough FEV1 was measured electronically by spirometry at morning (AM) investigational site visits, before administration of the AM dose of study drug and before albuterol/salbutamol administration. The highest FEV1 value from 3 acceptable and 2 reproducible maneuvers was used. All FEV1 data were submitted to a central reading center for evaluation. The p-values for the treatment comparisons to placebo are from an MMRM model excluding FLOVENT DISKUS data: change from baseline = baseline FEV1 + sex + age + treatment + visit + treatment\*visit with an unstructured covariance matrix assumed.

    Time frame: Baseline (Day 1, pre-dose), During Study (Days 7, 14, 28, 56 and 84 pre-dose)

Secondary outcomes

  1. Change From Baseline In Weekly Average Of Daily Trough (Predose And Pre-Rescue Bronchodilator) Morning Peak Expiratory Flow (PEF) Over The 12-Week Treatment Period

    Peak expiratory flow was determined in the AM and in the PM, before administration of study or rescue medications using a handheld electronic peak flow meter. The highest value of triplicate measurements obtained was recorded by the subject's diary device. On mornings for which a treatment visit was scheduled (TV1 through TV9), the PEF was measured and recorded at the investigational site visit. Baseline trough AM PEF was defined as the average of recorded (non-missing) trough AM PEF assessments over the 7 days directly preceding first study drug intake. The p-values for the treatment comparisons to placebo are from an MMRM model excluding FLOVENT DISKUS data: change from baseline = baseline PEF + sex + age + treatment + visit + treatment\*visit with an unstructured covariance matrix assumed.

    Time frame: Baseline (Days -7 to 1, am pre-dose), During Study (Days 2-84 am pre-dose)

  2. Change From Baseline In Weekly Average Of Daily Evening Peak Expiratory Flow (PEF) Over The 12-Week Treatment Period

    Peak expiratory flow was determined in the AM and in the PM, before administration of study or rescue medications using a handheld electronic peak flow meter. The highest value of triplicate measurements obtained was recorded by the subject's diary device. PM PEF baseline was defined as the average of recorded (nonmissing) PM PEF assessments over the 7 days directly preceding first study drug intake. The p-values for the treatment comparisons to placebo are from an MMRM model excluding FLOVENT DISKUS data: change from baseline = baseline PEF + sex + age + treatment + visit + treatment\*visit with an unstructured covariance matrix assumed.

    Time frame: Baseline (Days -7 to 1, am pre-dose), During Study (Days 2-84 am pre-dose)

  3. Change From Baseline in the Percentage of Rescue-Free 24-hour Periods During the 12-Week Treatment Period

    The number of inhalations of rescue medication used each day and each night was recorded in the subject's diary device. Change from baseline in the percentage of rescue-free 24-hour periods was analyzed with a marginal (also called population averaged) logistic model. The model included 2 time points of measurement for each subject: the baseline and the treatment period. The model contained covariates for sex, age, and treatment. The model for the 2 time points was considered as an incomplete randomized block model, with each subject as a block, receiving the baseline level in 1 sub-block and either active treatment or placebo in the other sub-block. The generalized estimating equation (GEE) algorithm was used to fit the model, using a robust estimator for the variance which provided a proper adjustment for possible correlation between the 2 measurements on each subject. Measure type are estimated mean and measure of dispersion is the standard error of the estimated mean.

    Time frame: Baseline (Days -7 to -1), During Study (Days 1-84)

  4. Kaplan-Meier Estimate of Probability of Remaining in the Study at Week 12

    The time to withdrawal due to stopping criteria was compared between the treatment groups with the log rank test. The Kaplan-Meier estimate of the probability of remaining in the study at week 12 with 95% CI was presented by treatment group. Subjects who completed the study were censored at the date of completion, subjects who withdrew for reasons other than stopping criteria were censored at the time of withdrawal. Stopping criteria were based on day subject first met stopping criteria, using subject's diary data and asthma exacerbations recorded in CRF.

    Time frame: Day 1 to Day 84

  5. Area Under The Curve From Time 0 Until The Last Measurable Concentration (AUC0-t) of Fp

    Approximately 20% of subjects randomized to the study and distributed across preselected study sites were to participate in fluticasone propionate pharmacokinetic assessments (the pharmacokinetic cohort). Subjects who had received fluticasone propionate in any form (orally, inhaled, or nasal) within 14 days of Day 1 were not permitted to participate in pharmacokinetic assessments.

    Time frame: Day 1: predose (within 10 minutes of treatment administration), and 5, 10, 15, 30, and 45 minutes, 1 hour, 1 hour 15 minutes, 1 hour 30 minutes, and 2, 4, 8, and 12 hours postdose

  6. Maximum Observed Plasma Concentration (Cmax) of Fp

    Approximately 20% of subjects randomized to the study and distributed across preselected study sites were to participate in fluticasone propionate pharmacokinetic assessments (the pharmacokinetic cohort). Subjects who had received fluticasone propionate in any form (orally, inhaled, or nasal) within 14 days of Day 1 were not permitted to participate in pharmacokinetic assessments.

    Time frame: Day 1: predose (within 10 minutes of treatment administration), and 5, 10, 15, 30, and 45 minutes, 1 hour, 1 hour 15 minutes, 1 hour 30 minutes, and 2, 4, 8, and 12 hours postdose

  7. Time of Maximum Concentration (Tmax) of Fp

    Approximately 20% of subjects randomized to the study and distributed across preselected study sites were to participate in fluticasone propionate pharmacokinetic assessments (the pharmacokinetic cohort). Subjects who had received fluticasone propionate in any form (orally, inhaled, or nasal) within 14 days of Day 1 were not permitted to participate in pharmacokinetic assessments.

    Time frame: Day 1: predose (within 10 minutes of treatment administration), and 5, 10, 15, 30, and 45 minutes, 1 hour, 1 hour 15 minutes, 1 hour 30 minutes, and 2, 4, 8, and 12 hours postdose

  8. Patients With Treatment-Emergent Adverse Experiences (TEAE) During the Treatment Period

    An adverse event was defined as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to the study drug. Severity was rated by the investigator on a scale of mild, moderate and severe, with severe= an AE which prevents normal daily activities. Relationship of AE to treatment was determined by the investigator. Serious AEs include death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, OR an important medical event that jeopardized the patient and required medical intervention to prevent the previously listed serious outcomes.

    Time frame: Day 1 -84

  9. Oropharyngeal Exam Findings at Each Study Visit

    Oropharyngeal examinations for visual evidence of oral candidiasis were conducted at all study visits. If the visual oropharyngeal examination was abnormal at the screening visit, the subject was excluded from entering the study and subjects with an abnormal oropharyngeal exam on Day 1 were not eligible for randomization. Any visual evidence of oral candidiasis during the treatment period of the study was evaluated by obtaining and analyzing a swab of the suspect area. Appropriate therapy was to be initiated immediately at the discretion of the investigator and was not to be delayed for culture confirmation. Subjects with a culture-positive infection could continue participation in the study on appropriate anti-infective therapy, provided this therapy was not prohibited by the protocol. If a subject required a protocol-prohibited medication for therapy, the subject was to be discontinued from the study. Data format: Time frame, \<signs of oral candidiasis?\> yes or no

    Time frame: Screening (week -3 to -2), Baseline (Week 0), Weeks 1, 2, 4, 8, 12

Other outcomes

  1. Change From Baseline In Trough (Morning Predose And Pre-Rescue Bronchodilator) Forced Expiratory Volume In 1 Second (FEV1) Over The 12-Week Treatment Period Inclusive of Flovent Diskus Data

    Trough FEV1 was measured electronically by spirometry at morning (AM) investigational site visits, before administration of the AM dose of study drug and before albuterol/salbutamol administration. The highest FEV1 value from 3 acceptable and 2 reproducible maneuvers was used. All FEV1 data were submitted to a central reading center for evaluation. The p-values for the treatment comparisons to placebo are from an MMRM model including data from all treatments: change from baseline = baseline FEV1 + sex + age + treatment + visit + treatment\*visit with an unstructured covariance matrix assumed.

    Time frame: Baseline (Day 1, pre-dose), During Study (Days 7, 14, 28, 56 and 84 pre-dose)

  2. Change From Baseline In Weekly Average Of Daily Trough (Predose And Pre-Rescue Bronchodilator) Morning Peak Expiratory Flow (PEF) Over The 12-Week Treatment Period Inclusive of Flovent Diskus Data

    Peak expiratory flow was determined in the AM and in the PM, before administration of study or rescue medications using a handheld electronic peak flow meter. The highest value of triplicate measurements obtained was recorded by the subject's diary device. On mornings for which a treatment visit was scheduled (TV1 through TV9), the PEF was measured and recorded at the investigational site visit. Baseline trough AM PEF was defined as the average of recorded (non-missing) trough AM PEF assessments over the 7 days directly preceding first study drug intake. The p-values for the treatment comparisons to placebo are from an MMRM model including all treatments: change from baseline = baseline PEF + sex + age + treatment + visit + treatment\*visit with an unstructured covariance matrix assumed.

    Time frame: Baseline (Days -7 to 1, am pre-dose), During Study (Days 2-84 am pre-dose)

  3. Change From Baseline In Weekly Average Of Daily Evening Peak Expiratory Flow (PEF) Over The 12-Week Treatment Period Inclusive of Flovent Diskus Data

    Peak expiratory flow was determined in the AM and in the PM, before administration of study or rescue medications using a handheld electronic peak flow meter. The highest value of triplicate measurements obtained was recorded by the subject's diary device. PM PEF baseline was defined as the average of recorded (nonmissing) PM PEF assessments over the 7 days directly preceding first study drug intake. The p-values for the treatment comparisons to placebo are from an MMRM model including all treatment groups: change from baseline = baseline PEF + sex + age + treatment + visit + treatment\*visit with an unstructured covariance matrix assumed.

    Time frame: Baseline (Days -7 to 1, am pre-dose), During Study (Days 2-84 am pre-dose)

07

Results

Posted Apr 12, 2017

Participant flow

A total of 1903 subjects with asthma were screened for enrollment into this study. Of the 994 subjects who were not enrolled, 983 were excluded on the basis of inclusion/exclusion criteria and 6 subjects withdrew consent, and for 5 the reason given was "other".

Pre-Assignment Period (Run-In Placebo)
Participant flow — Pre-Assignment Period (Run-In Placebo)
MilestonePlacebo MDPI (Run-In)Fp MDPI 12.5 mcgFp MDPI 25 mcgFp MDPI 50 mcgFp MDPI 100 mcgPlacebo MDPIFlovent Diskus 100mcg
Started909000000
Completed622000000
Not completed287000000
Withdrew: Inclusion/exclusion criteria93000000
Withdrew: Withdrawal by subject19000000
Withdrew: Randomization criteria not met153000000
Withdrew: Lost to follow-up7000000
Withdrew: Other15000000
Treatment Period
Participant flow — Treatment Period
MilestonePlacebo MDPI (Run-In)Fp MDPI 12.5 mcgFp MDPI 25 mcgFp MDPI 50 mcgFp MDPI 100 mcgPlacebo MDPIFlovent Diskus 100mcg
Started0103104104103104104
Safety population0103104104103104104
Full analysis set0102101102102102102
Completed0798392826384
Not completed0242112214120
Withdrew: Adverse event0000122
Withdrew: Withdrawal by subject0422551
Withdrew: Physician decision0000110
Withdrew: Non-compliance to study drug0100001
Withdrew: Protocol violation09652106
Withdrew: Pregnancy0020000
Withdrew: Sponsor request subject to be withdrawn0231113
Withdrew: Lost to follow-up0010221
Withdrew: Met stopping criteria08749206

Outcome measures

PrimaryChange From Baseline In Trough (Morning Predose And Pre-Rescue Bronchodilator) Forced Expiratory Volume In 1 Second (FEV1) Over The 12-Week Treatment Period

Trough FEV1 was measured electronically by spirometry at morning (AM) investigational site visits, before administration of the AM dose of study drug and before albuterol/salbutamol administration. The highest FEV1 value from 3 acceptable and 2 reproducible maneuvers was used. All FEV1 data were submitted to a central reading center for evaluation. The p-values for the treatment comparisons to placebo are from an MMRM model excluding FLOVENT DISKUS data: change from baseline = baseline FEV1 + sex + age + treatment + visit + treatment\*visit with an unstructured covariance matrix assumed.

Time frame:
Baseline (Day 1, pre-dose), During Study (Days 7, 14, 28, 56 and 84 pre-dose)
Reported as:
Least squares mean · liters
Change From Baseline In Trough (Morning Predose And Pre-Rescue Bronchodilator) Forced Expiratory Volume In 1 Second (FEV1) Over The 12-Week Treatment Period
litersFp MDPI 12.5 mcgFp MDPI 25 mcgFp MDPI 50 mcgFp MDPI 100 mcgPlacebo MDPIFlovent Diskus 100mcg
Change From Baseline In Trough (Morning Predose And Pre-Rescue Bronchodilator) Forced Expiratory Volume In 1 Second (FEV1) Over The 12-Week Treatment Period0.170 ± 0.03000.229 ± 0.02950.243 ± 0.02880.267 ± 0.03000.118 ± 0.0302—
Statistical analysis
  • Fp MDPI 12.5 mcg vs Fp MDPI 25 mcg vs Fp MDPI 50 mcg vs Fp MDPI 100 mcg vs Placebo MDPI · Regression, Linear · p = 0.0001 (The study was considered positive if the trend test was positive and the test involving the highest Fp MDPI dose (100 mcg twice daily) indicated significantly greater time averaged FEV1 mean than placebo.)
  • Fp MDPI 100 mcg vs Placebo MDPI · mixed model for repeated measures · p = 0.0005 (The study was considered positive if the trend test was positive and the test involving the highest Fp MDPI dose (100 mcg twice daily) indicated significantly greater time averaged FEV1 mean than placebo.) · Lsm difference: 0.149 · 95% CI 0.066 to 0.233
  • Fp MDPI 50 mcg vs Placebo MDPI · mixed model for repeated measures · p = 0.0027 · Lsm difference: 0.126 · 95% CI 0.044 to 0.208
  • Fp MDPI 25 mcg vs Placebo MDPI · mixed model for repeated measures · p = 0.0086 · Lsm difference: 0.111 · 95% CI 0.028 to 0.194
  • Fp MDPI 12.5 mcg vs Placebo MDPI · mixed model for repeated measures · p = 0.2227 · Lsm difference: 0.052 · 95% CI -0.032 to 0.136
SecondaryChange From Baseline In Weekly Average Of Daily Trough (Predose And Pre-Rescue Bronchodilator) Morning Peak Expiratory Flow (PEF) Over The 12-Week Treatment Period

Peak expiratory flow was determined in the AM and in the PM, before administration of study or rescue medications using a handheld electronic peak flow meter. The highest value of triplicate measurements obtained was recorded by the subject's diary device. On mornings for which a treatment visit was scheduled (TV1 through TV9), the PEF was measured and recorded at the investigational site visit. Baseline trough AM PEF was defined as the average of recorded (non-missing) trough AM PEF assessments over the 7 days directly preceding first study drug intake. The p-values for the treatment comparisons to placebo are from an MMRM model excluding FLOVENT DISKUS data: change from baseline = baseline PEF + sex + age + treatment + visit + treatment\*visit with an unstructured covariance matrix assumed.

Time frame:
Baseline (Days -7 to 1, am pre-dose), During Study (Days 2-84 am pre-dose)
Reported as:
Least squares mean · liters/minute
Change From Baseline In Weekly Average Of Daily Trough (Predose And Pre-Rescue Bronchodilator) Morning Peak Expiratory Flow (PEF) Over The 12-Week Treatment Period
liters/minuteFp MDPI 12.5 mcgFp MDPI 25 mcgFp MDPI 50 mcgFp MDPI 100 mcgPlacebo MDPIFlovent Diskus 100mcg
Change From Baseline In Weekly Average Of Daily Trough (Predose And Pre-Rescue Bronchodilator) Morning Peak Expiratory Flow (PEF) Over The 12-Week Treatment Period30.99 ± 4.60021.01 ± 4.52129.58 ± 4.39627.55 ± 4.6109.26 ± 4.755—
Statistical analysis
  • Fp MDPI 12.5 mcg vs Fp MDPI 25 mcg vs Fp MDPI 50 mcg vs Fp MDPI 100 mcg vs Placebo MDPI · Regression, Linear · p = 0.0017 (Significance at 0.05)
  • Fp MDPI 100 mcg vs Placebo MDPI · mixed model for repeated measures · p = 0.0060 (Significance at 0.05) · Lsm difference: 18.29 · 95% CI 5.28 to 31.29
  • Fp MDPI 50 mcg vs Placebo MDPI · mixed model for repeated measures · p = 0.0018 (Significance at 0.05) · Lsm difference: 20.32 · 95% CI 7.61 to 33.03
  • Fp MDPI 25 mcg vs Placebo MDPI · mixed model for repeated measures · p = 0.0741 (Significance at 0.05) · Lsm difference: 11.75 · 95% CI -1.15 to 24.64
  • Fp MDPI 12.5 mcg vs Placebo MDPI · mixed model for repeated measures · p = 0.0011 (Significance at 0.05) · Lsm difference: 21.72 · 95% CI 8.73 to 34.72
SecondaryChange From Baseline In Weekly Average Of Daily Evening Peak Expiratory Flow (PEF) Over The 12-Week Treatment Period

Peak expiratory flow was determined in the AM and in the PM, before administration of study or rescue medications using a handheld electronic peak flow meter. The highest value of triplicate measurements obtained was recorded by the subject's diary device. PM PEF baseline was defined as the average of recorded (nonmissing) PM PEF assessments over the 7 days directly preceding first study drug intake. The p-values for the treatment comparisons to placebo are from an MMRM model excluding FLOVENT DISKUS data: change from baseline = baseline PEF + sex + age + treatment + visit + treatment\*visit with an unstructured covariance matrix assumed.

Time frame:
Baseline (Days -7 to 1, am pre-dose), During Study (Days 2-84 am pre-dose)
Reported as:
Least squares mean · liters/minute
Change From Baseline In Weekly Average Of Daily Evening Peak Expiratory Flow (PEF) Over The 12-Week Treatment Period
liters/minuteFp MDPI 12.5 mcgFp MDPI 25 mcgFp MDPI 50 mcgFp MDPI 100 mcgPlacebo MDPIFlovent Diskus 100mcg
Change From Baseline In Weekly Average Of Daily Evening Peak Expiratory Flow (PEF) Over The 12-Week Treatment Period27.65 ± 4.47418.69 ± 4.34722.20 ± 4.23720.48 ± 4.4909.42 ± 4.588—
Statistical analysis
  • Fp MDPI 12.5 mcg vs Fp MDPI 25 mcg vs Fp MDPI 50 mcg vs Fp MDPI 100 mcg vs Placebo MDPI · Regression, Linear · p = 0.0434 (Significance at 0.05)
  • Fp MDPI 100 mcg vs Placebo MDPI · mixed model for repeated measures · p = 0.0852 (Significance at 0.05) · Lsm difference: 11.06 · 95% CI -1.54 to 23.66
  • Fp MDPI 50 mcg vs Placebo MDPI · mixed model for repeated measures · p = 0.0411 (Significance at 0.05) · Lsm difference: 12.78 · 95% CI 0.52 to 25.04
  • Fp MDPI 25 mcg vs Placebo MDPI · mixed model for repeated measures · p = 0.1428 (Significance at 0.05) · Lsm difference: 9.28 · 95% CI -3.14 to 21.69
  • Fp MDPI 12.5 mcg vs Placebo MDPI · mixed model for repeated measures · p = 0.0046 (Significance at 0.05) · Lsm difference: 18.23 · 95% CI 5.64 to 30.82
SecondaryChange From Baseline in the Percentage of Rescue-Free 24-hour Periods During the 12-Week Treatment Period

The number of inhalations of rescue medication used each day and each night was recorded in the subject's diary device. Change from baseline in the percentage of rescue-free 24-hour periods was analyzed with a marginal (also called population averaged) logistic model. The model included 2 time points of measurement for each subject: the baseline and the treatment period. The model contained covariates for sex, age, and treatment. The model for the 2 time points was considered as an incomplete randomized block model, with each subject as a block, receiving the baseline level in 1 sub-block and either active treatment or placebo in the other sub-block. The generalized estimating equation (GEE) algorithm was used to fit the model, using a robust estimator for the variance which provided a proper adjustment for possible correlation between the 2 measurements on each subject. Measure type are estimated mean and measure of dispersion is the standard error of the estimated mean.

Time frame:
Baseline (Days -7 to -1), During Study (Days 1-84)
Reported as:
Mean · percentage of total 24 hour periods
Change From Baseline in the Percentage of Rescue-Free 24-hour Periods During the 12-Week Treatment Period
percentage of total 24 hour periodsFp MDPI 12.5 mcgFp MDPI 25 mcgFp MDPI 50 mcgFp MDPI 100 mcgPlacebo MDPIFlovent Diskus 100mcg
Change From Baseline in the Percentage of Rescue-Free 24-hour Periods During the 12-Week Treatment Period34.08 ± 3.90931.76 ± 4.22928.06 ± 3.79924.07 ± 4.28321.30 ± 4.66829.82 ± 4.191
Statistical analysis
  • Fp MDPI 100 mcg vs Placebo MDPI · GEE · p = 0.66685 · Estimated mean difference from placebo: 2.76 · 95% CI -10.07 to 15.60The model contained covariates for sex, age, and treatment. The baseline level was estimated for all subjects combined, adjusted for covariates.
  • Fp MDPI 50 mcg vs Placebo MDPI · GEE · p = 0.26741 (The model contained covariates for sex, age, and treatment. The baseline level was estimated for all subjects combined, adjusted for covariates.) · Estimated mean difference from placebo: 6.76 · 95% CI -5.43 to 18.94
  • Fp MDPI 25 mcg vs Placebo MDPI · GEE · p = 0.09964 (The model contained covariates for sex, age, and treatment. The baseline level was estimated for all subjects combined, adjusted for covariates.) · Estimated mean difference from placebo: 10.45 · 95% CI -2.24 to 23.15
  • Fp MDPI 12.5 mcg vs Placebo MDPI · GEE · p = 0.03825 (The model contained covariates for sex, age, and treatment. The baseline level was estimated for all subjects combined, adjusted for covariates.) · Slope: 12.78 · 95% CI 0.44 to 25.11
SecondaryKaplan-Meier Estimate of Probability of Remaining in the Study at Week 12

The time to withdrawal due to stopping criteria was compared between the treatment groups with the log rank test. The Kaplan-Meier estimate of the probability of remaining in the study at week 12 with 95% CI was presented by treatment group. Subjects who completed the study were censored at the date of completion, subjects who withdrew for reasons other than stopping criteria were censored at the time of withdrawal. Stopping criteria were based on day subject first met stopping criteria, using subject's diary data and asthma exacerbations recorded in CRF.

Time frame:
Day 1 to Day 84
Reported as:
Number · probability
Kaplan-Meier Estimate of Probability of Remaining in the Study at Week 12
probabilityFp MDPI 12.5 mcgFp MDPI 25 mcgFp MDPI 50 mcgFp MDPI 100 mcgPlacebo MDPIFlovent Diskus 100mcg
Kaplan-Meier Estimate of Probability of Remaining in the Study at Week 120.8041 (0.7067 to 0.8720)0.7895 (0.6927 to 0.8589)0.9077 (0.8300 to 0.9509)0.7657 (0.6660 to 0.8392)0.5655 (0.4528 to 0.6636)0.8272 (0.7332 to 0.8905)
Statistical analysis
  • Fp MDPI 100 mcg vs Placebo MDPI · Log Rank · p = 0.2841 (Significance at 0.05)
  • Fp MDPI 50 mcg vs Placebo MDPI · Log Rank · p = <0.0001 (Significance at 0.05)
  • Fp MDPI 25 mcg vs Placebo MDPI · Log Rank · p = 0.0008 (Significance at 0.05)
  • Fp MDPI 12.5 mcg vs Placebo MDPI · Log Rank · p = 0.0010 (Significance at 0.05)
SecondaryArea Under The Curve From Time 0 Until The Last Measurable Concentration (AUC0-t) of Fp

Approximately 20% of subjects randomized to the study and distributed across preselected study sites were to participate in fluticasone propionate pharmacokinetic assessments (the pharmacokinetic cohort). Subjects who had received fluticasone propionate in any form (orally, inhaled, or nasal) within 14 days of Day 1 were not permitted to participate in pharmacokinetic assessments.

Time frame:
Day 1: predose (within 10 minutes of treatment administration), and 5, 10, 15, 30, and 45 minutes, 1 hour, 1 hour 15 minutes, 1 hour 30 minutes, and 2, 4, 8, and 12 hours postdose
Reported as:
Mean · pg*hr/mL
Area Under The Curve From Time 0 Until The Last Measurable Concentration (AUC0-t) of Fp
pg*hr/mLFp MDPI 12.5 mcgFp MDPI 25 mcgFp MDPI 50 mcgFp MDPI 100 mcgPlacebo MDPIFlovent Diskus 100mcg
Area Under The Curve From Time 0 Until The Last Measurable Concentration (AUC0-t) of Fp21.6 ± 27.0942.0 ± 23.2163.2 ± 22.64153.8 ± 91.42—10.4 ± 45.65
SecondaryMaximum Observed Plasma Concentration (Cmax) of Fp

Approximately 20% of subjects randomized to the study and distributed across preselected study sites were to participate in fluticasone propionate pharmacokinetic assessments (the pharmacokinetic cohort). Subjects who had received fluticasone propionate in any form (orally, inhaled, or nasal) within 14 days of Day 1 were not permitted to participate in pharmacokinetic assessments.

Time frame:
Day 1: predose (within 10 minutes of treatment administration), and 5, 10, 15, 30, and 45 minutes, 1 hour, 1 hour 15 minutes, 1 hour 30 minutes, and 2, 4, 8, and 12 hours postdose
Reported as:
Mean · pg/mL
Maximum Observed Plasma Concentration (Cmax) of Fp
pg/mLFp MDPI 12.5 mcgFp MDPI 25 mcgFp MDPI 50 mcgFp MDPI 100 mcgPlacebo MDPIFlovent Diskus 100mcg
Maximum Observed Plasma Concentration (Cmax) of Fp5.4 ± 4.2310.0 ± 5.3512.9 ± 5.1333.6 ± 15.49—23.4 ± 10.73
SecondaryTime of Maximum Concentration (Tmax) of Fp

Approximately 20% of subjects randomized to the study and distributed across preselected study sites were to participate in fluticasone propionate pharmacokinetic assessments (the pharmacokinetic cohort). Subjects who had received fluticasone propionate in any form (orally, inhaled, or nasal) within 14 days of Day 1 were not permitted to participate in pharmacokinetic assessments.

Time frame:
Day 1: predose (within 10 minutes of treatment administration), and 5, 10, 15, 30, and 45 minutes, 1 hour, 1 hour 15 minutes, 1 hour 30 minutes, and 2, 4, 8, and 12 hours postdose
Reported as:
Mean · hours
Time of Maximum Concentration (Tmax) of Fp
hoursFp MDPI 12.5 mcgFp MDPI 25 mcgFp MDPI 50 mcgFp MDPI 100 mcgPlacebo MDPIFlovent Diskus 100mcg
Time of Maximum Concentration (Tmax) of Fp1.2 ± 0.971.4 ± 2.431.7 ± 2.551.1 ± 0.95—1.7 ± 2.61
SecondaryPatients With Treatment-Emergent Adverse Experiences (TEAE) During the Treatment Period

An adverse event was defined as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to the study drug. Severity was rated by the investigator on a scale of mild, moderate and severe, with severe= an AE which prevents normal daily activities. Relationship of AE to treatment was determined by the investigator. Serious AEs include death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, OR an important medical event that jeopardized the patient and required medical intervention to prevent the previously listed serious outcomes.

Time frame:
Day 1 -84
Reported as:
Count of participants · Participants
Patients With Treatment-Emergent Adverse Experiences (TEAE) During the Treatment Period
ParticipantsFp MDPI 12.5 mcgFp MDPI 25 mcgFp MDPI 50 mcgFp MDPI 100 mcgPlacebo MDPIFlovent Diskus 100mcg
Any adverse event (AE)313236373132
Severe AE003233
Treatment-related AE633211
Deaths000000
Other serious AE001222
Withdrawn from treatment due to AE000122
SecondaryOropharyngeal Exam Findings at Each Study Visit

Oropharyngeal examinations for visual evidence of oral candidiasis were conducted at all study visits. If the visual oropharyngeal examination was abnormal at the screening visit, the subject was excluded from entering the study and subjects with an abnormal oropharyngeal exam on Day 1 were not eligible for randomization. Any visual evidence of oral candidiasis during the treatment period of the study was evaluated by obtaining and analyzing a swab of the suspect area. Appropriate therapy was to be initiated immediately at the discretion of the investigator and was not to be delayed for culture confirmation. Subjects with a culture-positive infection could continue participation in the study on appropriate anti-infective therapy, provided this therapy was not prohibited by the protocol. If a subject required a protocol-prohibited medication for therapy, the subject was to be discontinued from the study. Data format: Time frame, \<signs of oral candidiasis?\> yes or no

Time frame:
Screening (week -3 to -2), Baseline (Week 0), Weeks 1, 2, 4, 8, 12
Reported as:
Count of participants · Participants
Oropharyngeal Exam Findings at Each Study Visit
ParticipantsFp MDPI 12.5 mcgFp MDPI 25 mcgFp MDPI 50 mcgFp MDPI 100 mcgPlacebo MDPIFlovent Diskus 100mcg
Screening - Yes000000
Screening - No103104104103104104
Week 0 - Yes000000
Week 0 - No103104104103104104
Week 1 - Yes000000
Week 1 - No93981001009498
Week 2 - Yes000000
Week 2 - No909399958393
Week 4 - Yes (positive culture)010000
Week 4 - No888997917590
Week 8 - Yes000000
Week 8 - No848592846683
Week 12 - Yes000000
Week 12 - No10210210310097101
Other pre-specifiedChange From Baseline In Trough (Morning Predose And Pre-Rescue Bronchodilator) Forced Expiratory Volume In 1 Second (FEV1) Over The 12-Week Treatment Period Inclusive of Flovent Diskus Data

Trough FEV1 was measured electronically by spirometry at morning (AM) investigational site visits, before administration of the AM dose of study drug and before albuterol/salbutamol administration. The highest FEV1 value from 3 acceptable and 2 reproducible maneuvers was used. All FEV1 data were submitted to a central reading center for evaluation. The p-values for the treatment comparisons to placebo are from an MMRM model including data from all treatments: change from baseline = baseline FEV1 + sex + age + treatment + visit + treatment\*visit with an unstructured covariance matrix assumed.

Time frame:
Baseline (Day 1, pre-dose), During Study (Days 7, 14, 28, 56 and 84 pre-dose)
Reported as:
Least squares mean · liters
Change From Baseline In Trough (Morning Predose And Pre-Rescue Bronchodilator) Forced Expiratory Volume In 1 Second (FEV1) Over The 12-Week Treatment Period Inclusive of Flovent Diskus Data
litersFp MDPI 12.5 mcgFp MDPI 25 mcgFp MDPI 50 mcgFp MDPI 100 mcgPlacebo MDPIFlovent Diskus 100mcg
Change From Baseline In Trough (Morning Predose And Pre-Rescue Bronchodilator) Forced Expiratory Volume In 1 Second (FEV1) Over The 12-Week Treatment Period Inclusive of Flovent Diskus Data0.172 ± 0.02930.232 ± 0.02880.245 ± 0.02800.268 ± 0.02920.120 ± 0.02940.234 ± 0.0288
Statistical analysis
  • Placebo MDPI vs Flovent Diskus 100mcg · mixed model for repeated measures · p = 0.0058 (Significance at 0.05) · Lsm difference: -0.114 · 95% CI -0.195 to -0.033
  • Fp MDPI 100 mcg vs Flovent Diskus 100mcg · mixed model for repeated measures · p = 0.4083 (Significance at 0.05) · Lsm difference: 0.034 · 95% CI -0.046 to 0.114
  • Fp MDPI 50 mcg vs Flovent Diskus 100mcg · mixed model for repeated measures · p = 0.7882 (Significance at 0.05) · Lsm difference: 0.011 · 95% CI -0.068 to 0.089
  • Fp MDPI 25 mcg vs Flovent Diskus 100mcg · mixed model for repeated measures · p = 0.9586 (Significance at 0.05) · Lsm difference: -0.002 · 95% CI -0.082 to 0.078
  • Fp MDPI 12.5 mcg vs Flovent Diskus 100mcg · mixed model for repeated measures · p = 0.1306 (Significance at 0.05) · Lsm difference: -0.062 · 95% CI -0.143 to 0.018
Other pre-specifiedChange From Baseline In Weekly Average Of Daily Trough (Predose And Pre-Rescue Bronchodilator) Morning Peak Expiratory Flow (PEF) Over The 12-Week Treatment Period Inclusive of Flovent Diskus Data

Peak expiratory flow was determined in the AM and in the PM, before administration of study or rescue medications using a handheld electronic peak flow meter. The highest value of triplicate measurements obtained was recorded by the subject's diary device. On mornings for which a treatment visit was scheduled (TV1 through TV9), the PEF was measured and recorded at the investigational site visit. Baseline trough AM PEF was defined as the average of recorded (non-missing) trough AM PEF assessments over the 7 days directly preceding first study drug intake. The p-values for the treatment comparisons to placebo are from an MMRM model including all treatments: change from baseline = baseline PEF + sex + age + treatment + visit + treatment\*visit with an unstructured covariance matrix assumed.

Time frame:
Baseline (Days -7 to 1, am pre-dose), During Study (Days 2-84 am pre-dose)
Reported as:
Least squares mean · liters/minute
Change From Baseline In Weekly Average Of Daily Trough (Predose And Pre-Rescue Bronchodilator) Morning Peak Expiratory Flow (PEF) Over The 12-Week Treatment Period Inclusive of Flovent Diskus Data
liters/minuteFp MDPI 12.5 mcgFp MDPI 25 mcgFp MDPI 50 mcgFp MDPI 100 mcgPlacebo MDPIFlovent Diskus 100mcg
Change From Baseline In Weekly Average Of Daily Trough (Predose And Pre-Rescue Bronchodilator) Morning Peak Expiratory Flow (PEF) Over The 12-Week Treatment Period Inclusive of Flovent Diskus Data31.20 ± 4.54421.27 ± 4.46529.63 ± 4.33927.66 ± 4.5509.30 ± 4.70026.96 ± 4.496
Statistical analysis
  • Placebo MDPI vs Flovent Diskus 100mcg · mixed model for repeated measures · p = 0.0068 (Significance at 0.05) · Lsm difference: -17.66 · 95% CI -30.43 to -4.89
  • Fp MDPI 100 mcg vs Flovent Diskus 100mcg · mixed model for repeated measures · p = 0.9135 (Significance at 0.05) · Lsm difference: 0.69 · 95% CI -11.84 to 13.23
  • Fp MDPI 50 mcg vs Flovent Diskus 100mcg · mixed model for repeated measures · p = 0.6689 (Significance at 0.05) · Lsm difference: 2.67 · 95% CI -9.58 to 14.92
  • Fp MDPI 25 mcg vs Flovent Diskus 100mcg · mixed model for repeated measures · p = 0.3691 (Significance at 0.05) · Lsm difference: -5.69 · 95% CI -18.12 to 6.74
  • Fp MDPI 12.5 mcg vs Flovent Diskus 100mcg · mixed model for repeated measures · p = 0.5072 (Significance at 0.05) · Lsm difference: 4.24 · 95% CI -8.31 to 16.78
Other pre-specifiedChange From Baseline In Weekly Average Of Daily Evening Peak Expiratory Flow (PEF) Over The 12-Week Treatment Period Inclusive of Flovent Diskus Data

Peak expiratory flow was determined in the AM and in the PM, before administration of study or rescue medications using a handheld electronic peak flow meter. The highest value of triplicate measurements obtained was recorded by the subject's diary device. PM PEF baseline was defined as the average of recorded (nonmissing) PM PEF assessments over the 7 days directly preceding first study drug intake. The p-values for the treatment comparisons to placebo are from an MMRM model including all treatment groups: change from baseline = baseline PEF + sex + age + treatment + visit + treatment\*visit with an unstructured covariance matrix assumed.

Time frame:
Baseline (Days -7 to 1, am pre-dose), During Study (Days 2-84 am pre-dose)
Reported as:
Least squares mean · liters/minute
Change From Baseline In Weekly Average Of Daily Evening Peak Expiratory Flow (PEF) Over The 12-Week Treatment Period Inclusive of Flovent Diskus Data
liters/minuteFp MDPI 12.5 mcgFp MDPI 25 mcgFp MDPI 50 mcgFp MDPI 100 mcgPlacebo MDPIFlovent Diskus 100mcg
Change From Baseline In Weekly Average Of Daily Evening Peak Expiratory Flow (PEF) Over The 12-Week Treatment Period Inclusive of Flovent Diskus Data28.00 ± 4.44218.97 ± 4.31522.27 ± 4.20620.47 ± 4.4539.70 ± 4.55724.95 ± 4.356
Statistical analysis
  • Placebo MDPI vs Flovent Diskus 100mcg · mixed model for repeated measures · p = 0.0158 (Significance at 0.05) · Lsm difference: -15.26 · 95% CI -27.63 to -2.88
  • Fp MDPI 100 mcg vs Flovent Diskus 100mcg · mixed model for repeated measures · p = 0.4709 (Significance at 0.05) · Lsm difference: -4.48 · 95% CI -16.69 to 7.721
  • Fp MDPI 50 mcg vs Flovent Diskus 100mcg · mixed model for repeated measures · p = 0.6572 (Significance at 0.05) · Lsm difference: -2.68 · 95% CI -14.55 to 9.19
  • Fp MDPI 25 mcg vs Flovent Diskus 100mcg · mixed model for repeated measures · p = 0.3292 (Significance at 0.05) · Lsm difference: -5.98 · 95% CI -18.01 to 6.05
  • Fp MDPI 12.5 mcg vs Flovent Diskus 100mcg · mixed model for repeated measures · p = 0.6237 (Significance at 0.05) · Lsm difference: 3.05 · 95% CI -9.16 to 15.26

Adverse events

Collected over Day 1 to 84. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Flovent Diskus 100mcg—2/104 (1.9%)5/104 (4.8%)
Fp MDPI 100 mcg—2/103 (1.9%)8/103 (7.8%)
Fp MDPI 12.5 mcg—0/103 (0%)10/103 (9.7%)
Fp MDPI 25 mcg—0/104 (0%)7/104 (6.7%)
Fp MDPI 50 mcg—1/104 (1%)10/104 (9.6%)
Placebo MDPI—2/104 (1.9%)8/104 (7.7%)
Most frequent serious events
Most frequent serious events
EventFlovent Diskus 100mcgFp MDPI 100 mcgFp MDPI 12.5 mcgFp MDPI 25 mcgFp MDPI 50 mcgPlacebo MDPI
AnaemiaBlood and lymphatic system disorders0/1041/1030/1030/1040/1040/104
Uterine haemorrhageReproductive system and breast disorders0/1041/1030/1030/1040/1040/104
HypertensionVascular disorders0/1041/1030/1030/1040/1040/104
Anaphylactic shockImmune system disorders1/1040/1030/1030/1040/1040/104
Groin abscessInfections and infestations1/1040/1030/1030/1040/1040/104
HypovolaemiaMetabolism and nutrition disorders0/1040/1030/1030/1040/1041/104
MigraineNervous system disorders0/1040/1030/1030/1041/1040/104
AsthmaRespiratory, thoracic and mediastinal disorders0/1040/1030/1030/1040/1041/104
Most frequent other events
Most frequent other events
EventFlovent Diskus 100mcgFp MDPI 100 mcgFp MDPI 12.5 mcgFp MDPI 25 mcgFp MDPI 50 mcgPlacebo MDPI
Upper respiratory tract infectionInfections and infestations4/1045/1037/1032/1043/1043/104
NasopharyngitisInfections and infestations1/1043/1034/1035/1047/1045/104

Baseline characteristics

Intent-to-Treat Analysis set

Age, Continuous
Age, Continuous(years)Fp MDPI 12.5 mcgFp MDPI 25 mcgFp MDPI 50 mcgFp MDPI 100 mcgPlacebo MDPIFlovent Diskus 100mcgTotal
Mean41.0 ± 16.9442.4 ± 16.0239.1 ± 16.0636.9 ± 15.3439.7 ± 15.2840.0 ± 15.3439.9 ± 15.87
Age, Customized
Age, Customized(Participants)Fp MDPI 12.5 mcgFp MDPI 25 mcgFp MDPI 50 mcgFp MDPI 100 mcgPlacebo MDPIFlovent Diskus 100mcgTotal
12-17 years1071495752
Adults (18-64 years)859086889393535
Adults (65+ years)87466435
Sex: Female, Male
Sex: Female, Male(Participants)Fp MDPI 12.5 mcgFp MDPI 25 mcgFp MDPI 50 mcgFp MDPI 100 mcgPlacebo MDPIFlovent Diskus 100mcgTotal
Female576360605563358
Male464144434941264
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Fp MDPI 12.5 mcgFp MDPI 25 mcgFp MDPI 50 mcgFp MDPI 100 mcgPlacebo MDPIFlovent Diskus 100mcgTotal
White919190858585527
Black10111214171781
Asian12240110
American Indian or Alaskan Native1000102
Pacific Islander0000101
Other0000011
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Fp MDPI 12.5 mcgFp MDPI 25 mcgFp MDPI 50 mcgFp MDPI 100 mcgPlacebo MDPIFlovent Diskus 100mcgTotal
Hispanic or Latino9471311650
Not Hispanic or Latino9410097909398572
Weight
Weight(kg)Fp MDPI 12.5 mcgFp MDPI 25 mcgFp MDPI 50 mcgFp MDPI 100 mcgPlacebo MDPIFlovent Diskus 100mcgTotal
Mean82.0 ± 23.2980.4 ± 19.6278.7 ± 23.0884.6 ± 23.5180.5 ± 20.0081.5 ± 23.5381.3 ± 22.22
Height
Height(cm)Fp MDPI 12.5 mcgFp MDPI 25 mcgFp MDPI 50 mcgFp MDPI 100 mcgPlacebo MDPIFlovent Diskus 100mcgTotal
Mean168.8 ± 10.54169.2 ± 8.89168.6 ± 10.33168.7 ± 10.94169.5 ± 9.25169.0 ± 9.39169.0 ± 9.88
Body Mass Index
Body Mass Index(kg/m^2)Fp MDPI 12.5 mcgFp MDPI 25 mcgFp MDPI 50 mcgFp MDPI 100 mcgPlacebo MDPIFlovent Diskus 100mcgTotal
Mean28.7 ± 7.4328.1 ± 6.4727.5 ± 6.7829.6 ± 7.5428.0 ± 6.6128.4 ± 7.3128.4 ± 7.04

3 further baseline measures are reported on the registry.

08

Study locations

189 sites
  • Teva Investigational Site 10165
    Homewood, Alabama, United States
  • Teva Investigational Site 11142
    Goodyear, Arizona, United States
  • Teva Investigational Site 10104
    Scottsdale, Arizona, United States
  • Teva Investigational Site 11149
    Little Rock, Arkansas, United States
  • Teva Investigational Site 10173
    Bakersfield, California, United States
  • Teva Investigational Site 10163
    Costa Mesa, California, United States
  • Teva Investigational Site 10156
    Encinitas, California, United States
  • Teva Investigational Site 11101
    Fountain Valley, California, United States
  • Teva Investigational Site 11111
    Fresno, California, United States
  • Teva Investigational Site 10151
    Granada Hills, California, United States
  • Teva Investigational Site 10157
    Huntington Beach, California, United States
  • Teva Investigational Site 10176
    Huntington Beach, California, United States
  • Teva Investigational Site 10147
    Long Beach, California, United States
  • Teva Investigational Site 11110
    Napa, California, United States
  • Teva Investigational Site 10136
    Newport Beach, California, United States
  • Teva Investigational Site 11122
    North Hollywood, California, United States
  • Teva Investigational Site 10140
    Orange, California, United States
  • Teva Investigational Site 10197
    Palmdale, California, United States
  • Teva Investigational Site 10185
    Redwood City, California, United States
  • Teva Investigational Site 10143
    Riverside, California, United States
  • Teva Investigational Site 11137
    Roseville, California, United States
  • Teva Investigational Site 10130
    San Diego, California, United States
  • Teva Investigational Site 10182
    San Diego, California, United States
  • Teva Investigational Site 10179
    San Jose, California, United States
  • Teva Investigational Site 10106
    Stockton, California, United States
  • Teva Investigational Site 10129
    Walnut Creek, California, United States
  • Teva Investigational Site 10145
    Centennial, Colorado, United States
  • Teva Investigational Site 10172
    Colorado Springs, Colorado, United States
  • Teva Investigational Site 10133
    Denver, Colorado, United States
  • Teva Investigational Site 10154
    Denver, Colorado, United States
  • Teva Investigational Site 11146
    Denver, Colorado, United States
  • Teva Investigational Site 10128
    Wheat Ridge, Colorado, United States
  • Teva Investigational Site 10196
    Waterbury, Connecticut, United States
  • Teva Investigational Site 10191
    Boynton Beach, Florida, United States
  • Teva Investigational Site 11127
    Brandon, Florida, United States
  • Teva Investigational Site 11118
    Clearwater, Florida, United States
  • Teva Investigational Site 11141
    Hialeah, Florida, United States
  • Teva Investigational Site 11140
    Kissimmee, Florida, United States
  • Teva Investigational Site 10137
    Miami, Florida, United States
  • Teva Investigational Site 10153
    Miami, Florida, United States
  • Teva Investigational Site 11120
    Miami, Florida, United States
  • Teva Investigational Site 11128
    Miami, Florida, United States
  • Teva Investigational Site 11132
    Miami, Florida, United States
  • Teva Investigational Site 11145
    Miami, Florida, United States
  • Teva Investigational Site 10171
    Ocala, Florida, United States
  • Teva Investigational Site 10178
    Sarasota, Florida, United States
  • Teva Investigational Site 11103
    South Miami, Florida, United States
  • Teva Investigational Site 10161
    Tallahassee, Florida, United States
  • Teva Investigational Site 10139
    Tampa, Florida, United States
  • Teva Investigational Site 11114
    Albany, Georgia, United States
  • Teva Investigational Site 10111
    Columbus, Georgia, United States
  • Teva Investigational Site 11124
    Columbus, Georgia, United States
  • Teva Investigational Site 10180
    Gainesville, Georgia, United States
  • Teva Investigational Site 10168
    Lawrenceville, Georgia, United States
  • Teva Investigational Site 11109
    Idaho Falls, Idaho, United States
  • Teva Investigational Site 10116
    Meridian, Idaho, United States
  • Teva Investigational Site 10127
    South Bend, Indiana, United States
  • Teva Investigational Site 10184
    Iowa City, Iowa, United States
  • Teva Investigational Site 10113
    Metairie, Louisiana, United States
  • Teva Investigational Site 10164
    Bangor, Maine, United States
  • Teva Investigational Site 10158
    Bethesda, Maryland, United States
  • Teva Investigational Site 10110
    Largo, Maryland, United States
  • Teva Investigational Site 10177
    Wheaton, Maryland, United States
  • Teva Investigational Site 10138
    North Dartmouth, Massachusetts, United States
  • Teva Investigational Site 10146
    North Dartmouth, Massachusetts, United States
  • Teva Investigational Site 10131
    Minneapolis, Minnesota, United States
  • Teva Investigational Site 10175
    Saint Louis, Missouri, United States
  • Teva Investigational Site 10189
    Saint Louis, Missouri, United States
  • Teva Investigational Site 11147
    Saint Louis, Missouri, United States
  • Teva Investigational Site 10118
    Bellevue, Nebraska, United States
  • Teva Investigational Site 10150
    Omaha, Nebraska, United States
  • Teva Investigational Site 11144
    Omaha, Nebraska, United States
  • Teva Investigational Site 11136
    Henderson, Nevada, United States
  • Teva Investigational Site 10114
    Bricktown, New Jersey, United States
  • Teva Investigational Site 10193
    Cherry Hill, New Jersey, United States
  • Teva Investigational Site 10101
    Hillsborough, New Jersey, United States
  • Teva Investigational Site 10155
    Skillman, New Jersey, United States
  • Teva Investigational Site 10188
    West Orange, New Jersey, United States
  • Teva Investigational Site 11113
    Albuquerque, New Mexico, United States
  • Teva Investigational Site 10187
    Brooklyn, New York, United States
  • Teva Investigational Site 10120
    New York, New York, United States
  • Teva Investigational Site 10190
    Newburgh, New York, United States
  • Teva Investigational Site 10167
    North Syracuse, New York, United States
  • Teva Investigational Site 10112
    Rochester, New York, United States
  • Teva Investigational Site 10105
    High Point, North Carolina, United States
  • Teva Investigational Site 10122
    Raleigh, North Carolina, United States
  • Teva Investigational Site 10194
    Canton, Ohio, United States
  • Teva Investigational Site 10107
    Cincinnati, Ohio, United States
  • Teva Investigational Site 10123
    Cincinnati, Ohio, United States
  • Teva Investigational Site 10144
    Columbus, Ohio, United States
  • Teva Investigational Site 11135
    Dayton, Ohio, United States
  • Teva Investigational Site 11115
    Middleburg Heights, Ohio, United States
  • Teva Investigational Site 10160
    Oklahoma City, Oklahoma, United States
  • Teva Investigational Site 10174
    Oklahoma City, Oklahoma, United States
  • Teva Investigational Site 10198
    Oklahoma City, Oklahoma, United States
  • Teva Investigational Site 11108
    Ashland, Oregon, United States
  • Teva Investigational Site 10132
    Eugene, Oregon, United States
  • Teva Investigational Site 10135
    Medford, Oregon, United States
  • Teva Investigational Site 10142
    Portland, Oregon, United States
  • Teva Investigational Site 11104
    Normal, Pennsylvania, United States

Showing the first 100 of 189 sites across 9 countries. Choose a country and city above to see the rest.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2012, a primary completion of Jul 2013 and a completion of Jul 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2017, 3 years 9 months after primary completion. A results delay was requested in Mar 2015.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 22, 2011
First posted
Nov 24, 2011
Start
Jan 2012
Primary completionActual
Jul 2013
CompletionActual
Jul 2013
Results delay requested
Mar 19, 2015
Results first posted
Apr 12, 2017
Last update
Jun 5, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 5, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01479621
Collaborators
PPD DEVELOPMENT, LP
Responsible party
Sponsor
First posted
Nov 24, 2011
Start date
Jan 2012
Primary completion
Jul 2013
Completion
Jul 2013
Results posted
Apr 12, 2017
Last update
Jun 5, 2017

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fluticasone

Start the discussion